Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Public ClinicalTrials.gov record NCT06771115. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
Study identification
- NCT ID
- NCT06771115
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- VTX3232 30 mg Drug
- Placebo in combination with semaglutide Drug
- VTX3232 30 mg in combination with semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2025 (Actual)
- Primary completion
- Sep 10, 2025 (Actual)
- Completion
- Sep 10, 2025 (Actual)
- Last update posted
- Sep 29, 2026
2025
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 840005 | Birmingham | Alabama | 35235 | — |
| 840003 | Lake Forest | California | 92630 | — |
| 840011 | Long Beach | California | 90815 | — |
| 840001 | Largo | Florida | 33761 | — |
| 840012 | Ocoee | Florida | 34761 | — |
| 840016 | Port Orange | Florida | 32127 | — |
| 840014 | Newton | Kansas | 67114 | — |
| 840015 | Marrero | Louisiana | 70072 | — |
| 840017 | Marrero | Louisiana | 70072 | — |
| 840002 | Austin | Texas | 78705 | — |
| 840006 | Dallas | Texas | 75230 | — |
| 840013 | San Antonio | Texas | 78229 | — |
| 840018 | San Antonio | Texas | 78229 | — |
| 840010 | Waco | Texas | 76710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06771115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06771115 live on ClinicalTrials.gov.